Lifecore Biomedical, Inc.

LFCR

US5147661046

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 04:00:00 2024-07-12 pm EDT			5-day change	1st Jan Change
5.03 ^USD	-2.90%		+2.86%	-18.74%

Jul. 01	Lifecore Biomedical Agrees to Add 4 Board Members Under 22NW Deal to Avoid Proxy Fight	MT
Jul. 01	Lifecore Biomedical Announces Cooperation Agreement with 22NW	CI

Landec Corporation Reports Unaudited Consolidated Impairment of Goodwill for Second Quarter Ended November 28, 2021

January 05, 2022 at 04:05 pm EST

Landec Corporation reported unaudited consolidated impairment of goodwill of $32,057,000 for second quarter ended November 28, 2021.

Latest news about Lifecore Biomedical, Inc.

Lifecore Biomedical Agrees to Add 4 Board Members Under 22NW Deal to Avoid Proxy Fight	Jul. 01	MT
Lifecore Biomedical Announces Cooperation Agreement with 22NW	Jul. 01	CI
Lifecore Biomedical, Inc. Announces Board Changes	Jul. 01	CI
Lifecore Biomedical, Inc.(NasdaqGS:LFCR) added to Russell Small Cap Comp Value Index	Jun. 30	CI
Lifecore Biomedical, Inc.(NasdaqGS:LFCR) added to Russell Small Cap Completeness Index	Jun. 30	CI
Lifecore Biomedical, Inc.(NasdaqGS:LFCR) dropped from Russell 3000E Growth Index	Jun. 30	CI
Lifecore Biomedical, Inc.(NasdaqGS:LFCR) added to Russell 2000 Index	Jun. 30	CI
Lifecore Biomedical, Inc.(NasdaqGS:LFCR) added to Russell 3000E Value Index	Jun. 30	CI
Lifecore Biomedical, Inc.(NasdaqGS:LFCR) added to Russell 3000E Index	Jun. 30	CI
Lifecore Biomedical, Inc.(NasdaqGS:LFCR) added to Russell 2500 Value Index	Jun. 30	CI
Lifecore Biomedical, Inc.(NasdaqGS:LFCR) added to Russell 3000 Value Index	Jun. 30	CI
Lifecore Biomedical, Inc.(NasdaqGS:LFCR) added to Russell 2000 Value Index	Jun. 30	CI
Lifecore Biomedical, Inc.(NasdaqGS:LFCR) dropped from Russell Microcap Growth Index	Jun. 30	CI
Lifecore Biomedical, Inc.(NasdaqGS:LFCR) added to Russell 2000 Dynamic Index	Jun. 30	CI
Lifecore Biomedical, Inc.(NasdaqGS:LFCR) added to Russell Microcap Value Index	Jun. 30	CI
Lifecore Biomedical, Inc.(NasdaqGS:LFCR) added to Russell 2500 Index	Jun. 30	CI
Lifecore Biomedical, Inc.(NasdaqGS:LFCR) added to Russell 3000 Index	Jun. 30	CI
22NW Fund Submits Shareholder Proposals to Lifecore Biomedical	Jun. 11	CI
22NW Fund Nominates Candidates to the Board of Lifecore Biomedical	May. 20	CI
Lifecore Biomedical, Inc. and Curation Foods, Inc. Enters into That Certain Seventh Amendment to Credit Agreement	May. 14	CI
Lifecore Biomedical, Inc. Engages BDO USA, P.C. as Independent Registered Public Accounting Firm	Apr. 30	CI
Lifecore Biomedical Gets Nasdaq Warning Over Delayed Quarterly Report	Apr. 19	MT
Lifecore Biomedical, Inc. Provides Revenue Guidance for Full Year Fiscal 2024	Apr. 01	CI
Lifecore Biomedical Searches for New Auditor for Fiscal Year 2024	Mar. 27	MT
Top Midday Decliners	Mar. 20	MT

Chart Lifecore Biomedical, Inc.

Duration

Period

More charts

Lifecore Biomedical, Inc. is a fully integrated contract development and manufacturing organization (CDMO). The Company designs, develops, manufactures and sells differentiated products for biomaterials markets and license technology applications to partners. The Company offers highly differentiated capabilities in the development, fill and finish of sterile, injectable-grade pharmaceutical products in syringes and vials. It is involved in the manufacture of pharmaceutical-grade sodium hyaluronate (HA) in bulk form, as well as formulated and filled syringes and vials for injectable products used in treating a spectrum of medical conditions and procedures. The Company uses its fermentation process and aseptic formulation and filling expertise to develop HA-based products for multiple applications and to take advantage of non-HA devices and drug opportunities.

Sector

Pharmaceuticals

Calendar

2024-07-29 - Q4 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for Lifecore Biomedical, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

5.03 USD

Average target price

6 USD

Spread / Average Target

+19.28%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
LIFECORE BIOMEDICAL, INC.	-18.74%	155M
ELI LILLY AND COMPANY	+62.66%	854B
NOVO NORDISK A/S	+40.42%	636B
JOHNSON & JOHNSON	-4.37%	361B
MERCK & CO., INC.	+17.16%	324B
ABBVIE INC.	+9.87%	301B
ASTRAZENECA PLC	+15.66%	247B
ROCHE HOLDING AG	+4.21%	230B
NOVARTIS AG	+17.90%	228B
AMGEN INC.	+14.86%	177B

Other Pharmaceuticals

Lifecore Biomedical, Inc.

Equities

LFCR

US5147661046

Pharmaceuticals

Landec Corporation Reports Unaudited Consolidated Impairment of Goodwill for Second Quarter Ended November 28, 2021

Latest news about Lifecore Biomedical, Inc.

Chart Lifecore Biomedical, Inc.

Company Profile

Income Statement Evolution

Ratings for Lifecore Biomedical, Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Pharmaceuticals